title: A preliminary analysis of microRNA-21 expression alteration after antipsychotic treatment in patients with schizophrenia.
abstract: Schizophrenia is a severe and debilitating psychiatric disorder of unknown etiology, and its diagnosis is essentially based on clinical symptoms. Despite growing evidence on the relation of altered expression of miRNAs and schizophrenia, most patients with schizophrenia usually had an extensive antipsychotic treatment history before miRNA expression profile analysis, and the pharmacological effects on miRNA expression are largely unknown. To overcome these impediments, miRNA microarray analysis was performed in peripheral blood mononuclear cells (PBMCs) obtained from patients with schizophrenia who were not on antipsychotic medication and healthy controls. Then, using quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR), we verified the top 10 miRNAs with the highest fold-change values from microarray analysis in 82 patients with schizophrenia and 43 healthy controls, and nine miRNAs demonstrated significant differences in expression levels. Finally, we compared these nine miRNA profiles before and after antipsychotic treatment. Our results revealed that serum miR-21 expression decreased strikingly in patients after antipsychotic treatment. The change of miR-21 expression was negatively correlated with improvement of positive, general psychopathology, and aggressiveness symptoms. This study preliminarily analyzed the possible changes in circulating miRNAs expression in response to antipsychotic medication for schizophrenia, and the molecular mechanisms of this needs to be further explored.
authors: Department of Psychiatry and Psychology, Second Military Medical University, Shanghai 200433, People's Republic of China; Department of Neurology, No. 102 Hospital of Chinese People's Liberation Army, Changzhou, Jiangsu 213003, People's Republic of China.
authors: Sheng-Dong
authors: SD
authors: Chen
authors: Department of Psychiatry and Psychology, Ping An Health Cloud Company Ltd. of China, Shanghai 200030, People's Republic of China.
authors: Xin-Yang
authors: XY
authors: Sun
authors: Department of Rehabilitation, No. 102 Hospital of Chinese People's Liberation Army, Changzhou, Jiangsu 213003, People's Republic of China.
authors: Wei
authors: W
authors: Niu
authors: Prevention and Treatment Center for Psychological Diseases, No. 102 Hospital of Chinese People's Liberation Army, Changzhou 213003, Jiangsu, People's Republic of China.
authors: Ling-Ming
authors: LM
authors: Kong
authors: Prevention and Treatment Center for Psychological Diseases, No. 102 Hospital of Chinese People's Liberation Army, Changzhou 213003, Jiangsu, People's Republic of China.
authors: Ming-Jun
authors: MJ
authors: He
authors: Cadre Ward, Chengdu Military General Hospital, Chengdu, Sichuan 610083, People's Republic of China.
authors: Hui-Min
authors: HM
authors: Fan
authors: GoPath Diagnostic Laboratory Co. Ltd, No. 801, Changwuzhong Road, Changzhou, Jiangsu 213164, People's Republic of China.
authors: Wan-Shuai
authors: WS
authors: Li
authors: Department of Laboratory, No. 102 Hospital of Chinese People's Liberation Army, Changzhou, Jiangsu 213003, People's Republic of China.
authors: Ai-Fang
authors: AF
authors: Zhong
authors: Department of Psychiatry and Psychology, Second Military Medical University, Shanghai 200433, People's Republic of China; Prevention and Treatment Center for Psychological Diseases, No. 102 Hospital of Chinese People's Liberation Army, Changzhou 213003, Jiangsu, People's Republic of China. Electronic address: zly102@126.com.
authors: Li-Yi
authors: LY
authors: Zhang
authors: GoPath Diagnostic Laboratory Co. Ltd, No. 801, Changwuzhong Road, Changzhou, Jiangsu 213164, People's Republic of China; GoPath Laboratories LLC, 1351 Barclay Blvd, Buffalo Grove, IL 60089, United States. Electronic address: luzb88@hotmail.com.
authors: Jim
authors: J
authors: Lu
mesh_terms: D000293:Adolescent; D000328:Adult; D000374:Aggression / Q000523:psychology; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D008297:Male; D035683:MicroRNAs / Q000378:metabolism*; D008875:Middle Aged; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012559:Schizophrenia / Q000188:drug therapy* / Q000378:metabolism; D012565:Schizophrenic Psychology; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; C524940:MIRN21 microRNA, human; D035683:MicroRNAs
keywords: Antipsychotics; Biomarker; MicroRNA; Schizophrenia